HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kempen, J.H. Search for Related Content PubMed Articles by Kempen, J.H.

Risk of Immune Recovery Uveitis in Patients With Cytomegalovirus Retinitis and the Acquired Immune Deficiency Syndrome

¹ Ophthalmology, Epidemiology, Johns Hopkins University (JHU), Baltimore, MD
² MedStar Research Institute, Hyattsville, MD
³ Ophthalmology, University of California, San Diego School of Medicine, La Jolla, CA
⁴ Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA
⁵ Ophthalmology, New York University School of Medicine, New York, NY
⁶ Medicine, The Mount Sinai Medical Center, New York, NY
⁷ Ophthalmology, Medicine, Epidemiology, JHU, Baltimore, MD

Commercial Relationships: J.H. Kempen, None; Y.I. Min, None; W.R. Freeman, None; G.N. Holland, None; D.N. Friedberg, None; D.T. Dieterich, None; D.A. Jabs, None.

Support: NEI U10 EY08052, U10 EY08057, U10 EY08067, NCRR GCRC grants 5MO1 RR00188, MO1 RR00052, others

Abstract

Purpose: To evaluate the risk of immune recovery uveitis (IRU) in patients with cytomegalovirus (CMV) retinitis and AIDS.

Methods: The Longitudinal Study of Ocular Complications of AIDS is ongoing at 19 AIDS ophthalmology centers. Enrollment data regarding the proportion of eyes with CMV retinitis which had clinically diagnosed IRU, cystoid macular edema (CME) and epiretinal membrane (ERM) were evaluated vis–a–vis potential risk factors.

Results: Among 1780 patients with AIDS enrolled between 2 September 1998 and 31 August 2004, 1701 (96%) had complete immune recovery (IR) and IRU data available; CMV retinitis was present in 374 (22%) of them (539 eyes). Thirty–six patients (50 eyes) had IRU (9.6%). Among those with IR (CD4+ T cell count 100 cells/µL and 50 cells/µL above nadir), 31 had IRU (17.6%, 95% confidence interval (CI): 12.3%–24.1%). In addition to IR, 25% retinal involvement (OR=2.72, p=0.014) was a risk factor for IRU, whereas male gender (OR=0.26, p=0.012) and posterior pole involvement (OR=0.43, p=0.039) were associated with lower IRU risk. Active retinitis (p<0.001) and detectable CMV DNA in peripheral blood (p<0.001) were not seen in patients with IRU. Use of cidofovir (ever) (OR=1.52, 95% CI: 0.63, 3.71) and current use of anti–CMV therapy (OR=0.78, 95% CI: 0.29, 2.09) were not significantly associated with IRU. Eyes with IRU were much more likely to have CME (45.5% vs. 3.7%, p<0.001) and ERM (48.9% vs. 13.3%, p<0.001) than those without IRU, and somewhat more likely to have visual acuity (VA)20/50 (38.0% vs. 26.3%, p=0.077), but not VA20/200 (14.0% vs. 13.8%, p=0.96).

Conclusions: The observed risk of IRU (17.6% of those with IR) in this multicenter study was substantial, although less than in some previous reports. Eyes with IRU had a higher burden of CME and ERM, and were more likely to have VA20/50 than eyes without IRU. Large retinal lesion size was confirmed as a risk factor. Large effects of cidofovir treatment (ever) and of anti–CMV therapy on risk were not observed, although moderate effects might not have been detectable with the available study power.

Keywords: AIDS/HIV • cytomegalovirus • clinical (human) or epidemiologic studies: outcomes/complications

© 2005, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. For permission to reproduce any part of this abstract, contact the ARVO Office at arvo{at}arvo.org.